Experimental confirmation of the 'protein traffic hypothesis' by routine diagnostic tests
by Borros M. Arneth
International Journal of Immunological Studies (IJIS), Vol. 1, No. 2, 2010

Abstract: The 'protein traffic hypothesis' suggests that the inflammation associated with autoimmune disease, trauma and disturbances of blood circulation is the result of misguided protein trafficking. The hypothesis divides the antigen spectrum into an intracellular component and an extracellular component. While the intracellular component is recognised by MHC class-I molecules and is presented to CD8 T-lymphocytes, the extracellular component is recognised by MHC class-II molecules and is presented to CD4 T-lymphocytes. To test this hypothesis, CD4 and CD8 T-cell counts of 271 HIV-negative patients of the University Hospital, Mainz, Germany were examined retrospectively. The results corroborate the observation that patients with autoimmune disease have a low CD4/CD8-ratio (0.5-1), while patients with acute infarction have a higher CD4/CD8-ratio (3-5). The normal CD4/CD8-ratio is 1.2-1.4. The results of this study confirm previous reports on the protein traffic hypothesis. Our data suggests that the CD4/CD8-ratio has broad clinical applications.

Online publication date: Mon, 30-Aug-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Immunological Studies (IJIS):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com